Pfizer and BioNTech said they have initiated a rolling submission of data to the US Food and Drug Administration after a request from the agency. They expect to complete the EUA submission in the coming days and say they will also submit clinical trial data to the European Medicines Agency and other agencies around the world.
Safety and effectiveness are key, said Dr. Paul Offit, a member of the committee and director of the Vaccine Education Center at Children’s Hospital of Philadelphia.
“The confidence of the American public depends on that, that you you’re recommending something that you would give to your own children,” Offit told CNN. “It all depends on the data. The data will tell us just how good these are. There should be a robust safety profile and a robust efficacy profile and immunogenicity profile. And if that’s true, speed doesn’t really matter, as long as they have those data.”
The Pfizer/BioNTech vaccine is already authorized for use in people as young as 5 and would be the first Covid-19 vaccine available for the youngest children.
Since the start of the pandemic, at least 11.4 million children have tested positive for Covid-19, the American Academy of Pediatrics reported Monday, with over 3.5 million cases reported in January alone. Children made up 22.8% of the total reported weekly cases for the week ending January 27.
“Pediatricians have seen firsthand the fear, stress and hardship that so many families of young children have endured as they await a vaccine,” Dr. Moira Szilagyi, president of the American Academy of Pediatrics, said in a statement. “We urge a transparent and data-driven process to evaluate this vaccine for this age group and look forward to offering its protection to our youngest children.”
The companies are continuing to test a three-dose version of the vaccine in the youngest kids.
In December, Pfizer extended its vaccine trial in younger children after two child-sized doses of the vaccine did not produce the expected immunity in 2- to 5-year-olds, although it did so for the babies up to age 2.
The companies said data on a third dose given at least eight weeks after the second dose is expected in the coming months, which will also be submitted to the FDA.
“As hospitalizations of children under 5 due to COVID-19 have soared, our mutual goal with the FDA is to prepare for future variant surges and provide parents with an option to help protect their children from this virus,” Pfizer Chairman and CEO Albert Bourla said. “Ultimately, we believe that three doses of the vaccine will be needed for children 6 months through 4 years of age to achieve high levels of protection against current and potential future variants.
“If two doses are authorized, parents will have the opportunity to begin a COVID-19 vaccination series for their children while awaiting potential authorization of a third dose.”
Read More: Pfizer and BioNTech seeking emergency use authorization from FDA for